Foghorn Therapeutics Retained Earnings 2011-2026 | FHTX

Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.

Possible uses include

reinvestment in development (R&D, equipment, marketing)
debt repayment
acquisition of other companies
creation of reserves for the future

A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.

The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.

Annual Retained Earnings Foghorn Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-558 M	-472 M	-373 M	-264 M	-163 M	-94.1 M	-43 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-43 M	-558 M	-281 M

Quarterly Retained Earnings Foghorn Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-611 M	-595 M	-577 M	-558 M	-539 M	-520 M	-497 M	-472 M	-447 M	-433 M	-404 M	-373 M	-344 M	-318 M	-291 M	-264 M	-235 M	-209 M	-186 M	-163 M	-163 M	-163 M	-163 M	-94.1 M	-94.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-94.1 M	-611 M	-349 M

Retained Earnings of other stocks in the Biotechnology industry

Issuer	Retained Earnings	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-158 M	-	2.43 %	$ 254 M	Germany
Adagene ADAG	-311 M	$ 1.65	7.91 %	$ 92.9 M	China
AstraZeneca PLC AZN	5.3 B	$ 93.52	-1.2 %	$ 96.9 B	Britain
Autolus Therapeutics plc AUTL	-1.1 B	$ 1.52	-16.3 %	$ 388 M	Britain
Alterity Therapeutics Limited ATHE	-182 M	$ 3.59	1.99 %	$ 8.64 B	Australia
Alexion Pharmaceuticals, Inc. ALXN	5.24 B	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	-131 M	-	-10.17 %	$ 12.2 K	USA
Biophytis SA BPTS	-17.1 M	-	-13.47 %	$ 169 M	France
Akero Therapeutics AKRO	-826 M	-	-	$ 3.67 B	USA
Biogen BIIB	19.3 B	$ 184.48	-1.67 %	$ 26.9 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	-108 M	-	-1.52 %	$ 24.7 M	USA
BioNTech SE BNTX	-410 M	$ 102.17	2.32 %	$ 27.2 B	Germany
Midatech Pharma plc MTP	-122 M	-	-18.52 %	$ 27.3 M	Britain
Can-Fite BioPharma Ltd. CANF	-166 M	$ 4.25	1.67 %	$ 9.25 B	Israel
Институт стволовых клеток человека ISKJ	69.4 M	-	-	-	Russia
Ascendis Pharma A/S ASND	-611 M	$ 207.49	2.22 %	$ 5 B	Danmark
ARCA biopharma ABIO	-83.7 M	-	1052.0 %	$ 415 M	USA
Acasti Pharma ACST	-221 M	-	4.01 %	$ 150 M	Canada
Catalyst Biosciences CBIO	-85.5 M	$ 10.84	0.46 %	$ 714 M	USA
Adaptimmune Therapeutics plc ADAP	-1.02 B	-	-15.15 %	$ 60.3 M	Britain
Corcept Therapeutics Incorporated CORT	544 M	$ 37.35	-0.4 %	$ 3.86 B	USA
Aeglea BioTherapeutics AGLE	-972 M	-	-	$ 1.01 B	USA
Catalyst Pharmaceuticals CPRX	285 M	$ 23.18	2.02 %	$ 2.75 B	USA
AIkido Pharma AIKI	-223 M	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	-301 M	-	-0.23 %	$ 916 M	USA
CureVac N.V. CVAC	-1.06 B	-	-	$ 867 M	Germany
Acer Therapeutics ACER	-141 M	-	2.71 %	$ 14 M	USA
Celldex Therapeutics CLDX	-1.56 B	$ 25.59	-6.54 %	$ 1.65 M	USA
Alpine Immune Sciences ALPN	-224 M	-	-	$ 2.17 B	USA
AlloVir ALVR	-715 M	-	4.14 %	$ 49.1 M	USA
Cellectis S.A. CLLS	-506 M	$ 4.22	-4.2 %	$ 116 M	France
Ayala Pharmaceuticals AYLA	-149 M	-	-	$ 7.46 M	Israel
Ampio Pharmaceuticals AMPE	-243 M	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	569 M	$ 29.43	6.09 %	$ 1.43 B	USA
Acorda Therapeutics ACOR	-1.19 B	-	-24.86 %	$ 820 K	USA
Applied Molecular Transport AMTI	-366 M	-	-	$ 10.1 M	USA
Brickell Biotech BBI	-172 M	-	-5.38 %	$ 6.06 M	USA
Aravive ARAV	-616 M	-	-13.39 %	$ 1.45 M	USA
Arena Pharmaceuticals ARNA	-2.12 B	-	-6.81 %	$ 3.04 B	USA
Arrowhead Pharmaceuticals ARWR	-1.63 B	$ 66.05	2.3 %	$ 8.83 B	USA
Athersys ATHX	-583 M	-	3.77 %	$ 22.4 M	USA
Avenue Therapeutics ATXI	-103 M	-	-52.27 %	$ 4.45 M	USA
Crinetics Pharmaceuticals CRNX	-952 M	$ 55.11	3.49 %	$ 4.45 B	USA
Abeona Therapeutics ABEO	-750 M	$ 5.14	-1.06 %	$ 110 M	USA
CRISPR Therapeutics AG CRSP	-1.37 B	$ 55.17	2.47 %	$ 4.65 B	Schweiz
AVROBIO AVRO	-477 M	-	1083.1 %	$ 745 M	USA
Axon Enterprise AXON	812 M	$ 632.29	0.09 %	$ 47.9 B	USA
ADiTx Therapeutics ADTX	-168 M	$ 0.81	1.96 %	$ 10.7 K	USA
Aytu BioScience AYTU	-334 M	$ 2.7	2.27 %	$ 17 M	USA